All Oncology News

FDA Grants Priority Review to Retifanlimab for Squamous Cell Carcinoma of the Anal Canal

January 21st 2021

January 21, 2021 - The FDA has granted priority review to a biologics license application for retifanlimab for the treatment of adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal who were intolerant of or who had progressed on platinum-based chemotherapy.

Parsaclisib Yields Encouraging Clinical Activity in Marginal Zone Lymphoma

January 21st 2021

Tycel Phillips, MD, highlighted the key findings of the phase 2 CITADEL-204 trial.

Search Continues for Agents to Provide Additive Benefit to Chemoradiation in Head and Neck Cancer

January 21st 2021

Nabil F. Saba, MD, FACP, discusses the results of the JAVELIN Head and Neck 100 trial, as well as data from other key, recent studies in head and neck cancer.

The Role of Cytoreductive Nephrectomy Remains Uncertain in mRCC

January 21st 2021

Justin T. Matulay, MD, discusses whether there is a role for cytoreductive nephrectomy in metastatic renal cell carcinoma, as well as key data that have helped guide this paradigm.

1-Year DFS Rates Similar Between Ibrutinib and Placebo Following Ibrutinib/Venetoclax in CLL

January 21st 2021

William G. Wierda, MD, PhD, discusses the latest CAPTIVATE findings in patients with chronic lymphocytic leukemia.

Personalized Y-90 Radiation Therapy Outperforms Standard Dosing in Advanced HCC

January 21st 2021

Beau Toskich, MD, discusses key results that demonstrate the benefit of personalized dosimetry, and offered advice to fellow clinicians as the field moves toward adopting this radiotherapeutic modality.

HER2-Directed Antibody-Drug Conjugates May Carve Out a Place in NSCLC Landscape

January 21st 2021

The current standard of care for patients with non–small cell lung cancer does not include therapies targeting HER2, a mutation that occurs in up to 4% of cases. However, data from recent studies of antibody-drug conjugates directed at HER2 activity are generating excitement about the potential utility of ADCs in this space.

Adult Nonmalignant Hematology Is an Endangered Field That Merits Protection

January 21st 2021

The scope of adult nonmalignant hematology can be broad and includes thrombotic and hemorrhagic disorders, transfusion medicine, hemoglobin disorders including sickle cell disease and thalassemia, anemia, thrombocytopenia, leukocytosis, leukopenia, and disorders of iron metabolism.

PANORAMA 3 Study Resets Expectations for Panobinostat in Multiple Myeloma

January 21st 2021

Andrew Spencer, MD, MBBS, FRACP, FRCPA discusses the significance of the PANORAMA 3 study in multiple myeloma.

HPV-Negative Cervical Cancer: Myth or An Area to Therapeutically Tackle?

January 20th 2021

The idea that HPV-negative cervical cancer is possible, especially in a disease that is mainly driven by HPV positivity, is not a unanimous opinion.